• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Bluejay Diagnostics Inc.

    7/3/24 4:01:01 PM ET
    $BJDX
    Medical/Dental Instruments
    Health Care
    Get the next $BJDX alert in real time by email
    SC 13G 1 l1cap_13g.htm SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    Bluejay Diagnostics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    095633400
    (CUSIP Number)
     
    June 27, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities and Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

     

    CUSIP No.  095633400   13G   Page 2 of 5 Pages

     

    1  NAME OF REPORTING PERSONS
       
      L1 Capital Global Opportunities Master Fund, Ltd.
    2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP
     

     

    (a)  ☐

      (b)  ☐
    3 SEC USE ONLY
       
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands 
      5                  SOLE VOTING POWER
         
         643,493(1)(2)
    NUMBER OF 6 SHARED VOTING POWER
    SHARES    
    BENEFICIALLY    0
    OWNED BY 7 SOLE DISPOSITIVE POWER
    EACH REPORTING    
    PERSON WITH    643,493(1)(2)
      8 SHARED DISPOSITIVE POWER
         
        0
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
       643,493(1)(2)
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     

     

    ☐

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
       9.99% (1)(2)
    12 TYPE OF REPORTING PERSON
     

     

    FI (3)

           

     

    (1)   Represents 134,179 shares of the Issuer’s Common Stock held by the Reporting Person, and 509,314 shares of Common Stock issuable upon the exercise of pre-funded warrants held by the Reporting Person which are exercisable within 60 days, subject to a 9.99% beneficial ownership limitation. Does not include 300,686 shares of Common Stock issuable upon the exercise of additional pre-funded warrants held by the Reporting Person, due to the 9.99% beneficial ownership limitation. Also does not include 1,840,000 shares of Common Stock underlying Class C Warrants held by the Reporting Person which are subject to a 9.99% beneficial ownership limitation and are also subject to the Issuer’s receipt of stockholder approval for the issuance of shares of Common Stock underlying such warrants, and to certain adjustments to the number of shares issuable upon exercise of such Warrants following the Issuer’s receipt of stockholder approval. Also does not include 920,000 shares of Common Stock underlying Class D Warrants held by the Reporting Person, which are subject to a 9.99% beneficial ownership limitation, and are also subject to certain adjustments to the number of shares issuable upon exercise of such Warrants following the Issuer’s receipt of stockholder approval.

     

    (2)   Based on 5,932,058 shares of Common Stock outstanding upon the closing of an offering as reported in the Issuer’s Prospectus dated June 27, 2024.

     

    (3)   The Reporting Person has not acquired the securities with any purpose, or with the effect, of changing or influencing the control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect, including any transaction subject to Rule 13d-3(b).

     

     
     

     

     

    CUSIP No.  095633400   13G   Page 3 of 5 Pages

     

    Item 1.

     

      (a) Name of Issuer:

     

    Bluejay Diagnostics, Inc.

     

     

    (b)

     

    Address of Issuer’s Principal Executive Offices:

     

    360 Massachusetts Avenue, Suite 203

    Acton, MA 01720

     

    Item 2.

     

    (a)  Name of Person Filing:
       
      L1 Capital Global Opportunities Master Fund, Ltd.
       
    (b)   Address of Principal Business Office or, if none, Residence:
       
     

    161A Shedden Road, 1 Artillery Court

    PO Box 10085

    Grand Cayman, Cayman Islands KY1-1001

       
    (c) Citizenship:
       
      Cayman Islands
       
    (d) Title of Class of Securities:
       
      Common Stock, par value $0.0001 per share
       
    (e)  CUSIP Number:
       
      095633400

     

    Item 3.

     

    Not applicable.

     

     

     
     

     

     

     
     CUSIP No. 095633400   13G   Page 4 of 5 Pages

     

    Item 4. Ownership.

     

    (a)–(c)   The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference.

     

        The percentage set forth on Row (11) of the cover page for the reporting person is based on 5,932,058 shares of Common Stock outstanding upon the closing of an offering based on the Issuer’s Prospectus dated June 27, 2024.

     

        David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer’s securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.

    Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

     

    CUSIP No.  095633400   13G   Page 5 of 5 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

       
      By:    L1 Capital Global Opportunities Master Fund, Ltd.
         
    July 3, 2024 By:  /s/ David Feldman
        David Feldman, Director

     

     

     

     

    Get the next $BJDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BJDX

    DatePrice TargetRatingAnalyst
    1/12/2022$10.00Buy
    Dawson James
    More analyst ratings

    $BJDX
    SEC Filings

    See more
    • Bluejay Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/28/25 5:18:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Bluejay Diagnostics Inc.

      DEF 14A - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/16/25 5:00:34 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Bluejay Diagnostics Inc.

      10-Q - Bluejay Diagnostics, Inc. (0001704287) (Filer)

      5/13/25 4:01:45 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bluejay Diagnostics Inc.

      SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      11/14/24 5:49:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bluejay Diagnostics Inc.

      SC 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      11/14/24 3:54:54 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Bluejay Diagnostics Inc.

      SC 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)

      7/3/24 4:01:01 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:17:42 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:16:33 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Scally Frances P

      3 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      10/11/23 7:21:49 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dey Svetlana bought $1,535 worth of shares (500 units at $3.07), increasing direct ownership by 50% to 1,500 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:17:42 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Dey Indranil bought $1,635 worth of shares (500 units at $3.27), increasing direct ownership by 2% to 28,526 units (SEC Form 4)

      4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)

      12/14/23 4:16:33 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

      ACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient testing solutions for critical care, today provided a 2025 mid-year business and corporate update. Recent Business Highlights and Developments: SYMON Clinical Program Update: The Company has initiated its pivotal SYMON-II clinical study, following the successful completion of the SYMON-I pilot study, for which a primary analysis highlighted that IL-6 levels within 24 hours of ICU admission may predict sepsis patient mortality out to 28 days. Currently, the Company is collecting, freezing and biobanking samples, w

      6/3/25 4:05:00 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

      ACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for presentation at the Society of Academic Emergency Medicine (SAEM) Annual Meeting, taking place in Philadelphia May 13-16, 2025. Results from SYMON-I, a pilot clinical study of interleukin-6 (IL-6) in sepsis patients intended or admitted for the intensive care unit (ICU), will be presented. SYMON-I evaluated IL-6 as a prognosticator for 28-day mortality and exploratory endpoints including 7-day mortality and microbiological positivity. "Early use of IL-6 in sepsis and septic shock pat

      4/15/25 7:00:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

      ACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into an agreement with institutional investors that are existing holders of warrants to purchase shares of common stock of the Company for cash (the "Existing Warrants"), wherein the investors agreed to exercise the Existing Warrants to purchase up 1,085,106 shares of common stock at a reduced exercise price of $3.42 per share, resulting in gross proceeds of approximately $3.7 million, before deducting

      4/7/25 5:21:14 PM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dawson James initiated coverage on Bluejay Diagnostics with a new price target

      Dawson James initiated coverage of Bluejay Diagnostics with a rating of Buy and set a new price target of $10.00

      1/12/22 9:00:51 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care

    $BJDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

      ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin "Ed" E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance. He will report to Neil Dey, Chief Executive Officer. Mr. Rule is a highly credentialed regulatory, quality and compliance professional with more than 15 years of industry experience. He has extensive training and expertise in medical device regulations in the U.S. and numerous international markets.

      3/28/22 7:00:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care
    • Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

      ACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay") a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company. "I am very pleased to welcome Mark on board as Chief Medical Advisor. I believe Mark's expansive clinical background and strategic leadership skills will be invaluable as we seek to develop the Compa

      1/5/22 8:15:00 AM ET
      $BJDX
      Medical/Dental Instruments
      Health Care